Alle Studien
RekrutierungHumane Pharmakologie (Phase I) - SonstigesInterventionell

A Single-Dose Pharmacokinetic Study of Lepodisiran in Participants with Varying Degrees of Liver Impairment and Participants with Normal Liver Function

This clinical trial is studying an experimental medicine called lepodisiran. The liver acts as a natural filter, breaking down medicines and clearing them from the bloodstream. When a person has liver problems, medicines can sometimes build up or clear out at different speeds. In this study, researchers want to see how the body absorbs, breaks down, and removes a single dose of lepodisiran. They will compare results between people with healthy livers and people with mild, moderate, or severe liver disease. Participants will receive one dose of the medicine and have regular blood tests and health checks. This information will help doctors understand whether future doses need to be adjusted for people with liver conditions. The study is open to adults aged 18 and over, and taking part is completely voluntary.

Auf einen Blick

Status
Rekrutierung
Phase
Humane Pharmakologie (Phase I) - Sonstiges
Sponsor
Eli Lilly & Co.
Einschreibeziel
6
Starten
16. Juni 2025

Worum geht es in dieser Studie?

When new medicines are created, scientists need to understand how they travel through the human body. This includes checking how the drug is absorbed, how it breaks down, and how it leaves the system. This early trial is testing an experimental medicine named lepodisiran to see how the body processes it.

The liver plays a vital role in processing many medicines. If someone has a liver condition, their liver may not process medicines in the normal way. This could mean a drug stays in the blood for longer, which might increase the risk of side effects. To make sure lepodisiran is safe for everyone, researchers need to compare how it behaves in people with healthy livers versus those with liver damage.

By comparing volunteers with normal liver function to those with mild, moderate, or severe liver problems, doctors can gather key safety details. The findings will help doctors decide whether people with liver conditions will need a lower dose or a different schedule if this medicine is approved in the future.

Wichtige Erkenntnisse

  • Tests how the body handles a single dose of the medicine lepodisiran.
  • Compares adults with healthy livers to those with mild, moderate, or severe liver conditions.
  • Helps doctors calculate safe, accurate doses for future patients with liver disease.
  • Includes health checks and regular blood tests to track drug levels.
  • Taking part is voluntary, and you are free to stop at any time.

Wer könnte berechtigt sein?

This trial is open to adults aged 18 and older. Both men and women may be able to join. The researchers are looking for two main groups of volunteers: people with healthy livers and people who have been diagnosed with mild, moderate, or severe liver conditions.

To ensure it is safe for you to take part, the study team will carry out health checks and blood tests. These tests will confirm how well your liver and kidneys are working and make sure you do not have any other medical conditions that would make taking part unsafe.

You may not be eligible if you take certain other medicines that could interfere with lepodisiran, or if you have recent serious health issues. The study doctors will review your complete medical history before you join.

Könnte diese Studie für Sie geeignet sein?

Beantworten Sie diese kurzen Fragen, um zu sehen, ob Sie möglicherweise berechtigt sind. Dies ist nur ein Leitfaden – das Forschungsteam trifft die endgültige Entscheidung.

  1. I am at least 18 years old.
  2. I have either normal liver function or a known mild, moderate, or severe liver condition.
  3. I am willing to attend clinic visits and have regular blood tests.
  4. I am able to give informed consent to take part.
  5. I can provide details of any regular medications I take.
Beantworten Sie jede Frage, um Ihr Ergebnis zu sehen.

Was beinhaltet die Teilnahme?

Taking part involves receiving a single dose of lepodisiran. Before you receive the medicine, you will attend a screening appointment to check your overall health. This usually includes blood tests, urine tests, and checks of your heart and blood pressure. You may need to stay at the clinic or visit regularly over several days or weeks so staff can take blood samples to measure medicine levels. Total time in the study will be discussed with you beforehand, and staff will monitor you closely for any changes in your health.

Potenzielle Risiken und Vorteile

Because this is an early-stage pharmacology study, taking part is not expected to improve your health or treat your liver condition directly. However, the study provides detailed health monitoring, and your participation helps doctors learn how to treat future patients safely. Like all new medicines, lepodisiran may cause unexpected side effects or mild discomfort from procedures like blood tests. Your safety is closely watched at all times, and you can choose to leave the study at any point without it affecting your regular NHS medical care.

Standorte (1)

Einige Standortangaben sind ungefähr. Wir arbeiten daran, dies zu verbessern — bitte überprüfen Sie die Angaben mit dem Versuchsteam, bevor Sie reisen.
  • —
    Unbestätigt
    Ungarn

Häufige Fragen

Was ist das Hauptziel dieser Studie?

The goal is to see how different levels of liver health affect the way the body processes a single dose of lepodisiran.

Will this medicine treat my liver disease?

No. This study is not designed to treat or cure liver disease. It only looks at how the body handles the medicine.

Wie wird das Medikament verabreicht?

Lepodisiran is given as a single dose during the trial, and the study team will guide you on how it is administered.

Do I have to pay to take part?

No, you do not pay for the study medicine or tests. Travel costs and time are often reimbursed by the study team.

Kann ich die Studie verlassen, wenn ich meine Meinung ändere?

Yes. You are free to withdraw from the trial at any time, for any reason, without your normal medical care being affected.

Wie Sie mehr erfahren können

Sprechen Sie immer mit Ihrem Hausarzt oder Spezialisten, bevor Sie sich entscheiden, an einer Studie teilzunehmen.

Interessiert daran, teilzunehmen?

Registrieren Sie Ihr Interesse

Teilen Sie Ihre Details und das Forschungsteam für "A Single-Dose Pharmacokinetic Study of Lepodisiran in Partic… wird Sie kontaktieren, wenn Sie möglicherweise infrage kommen. Sprechen Sie immer mit Ihrem Hausarzt, bevor Sie zustimmen, teilzunehmen.

Diskussion

Community-Diskussion

Bereitgestellt von unserem Forum bei community.patient.info. Bitte seien Sie respektvoll — dies ist kein medizinischer Rat.